Toronto, Ontario--(Newsfile Corp. - December 23, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the " Company " or " Telo ") is pleased to announce that, further to its news release dated December 12, 2024, it has closed an over-subscribed, non-brokered private placement of 25,459,000 units (" Units ") at a price of $0.10 per Unit for gross proceeds of $2,545,900 (the " Offering "). Each Unit consists... Read More

Toronto, Ontario--(Newsfile Corp. - December 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the " Company " or " Telo ") is pleased to announce a non-brokered private placement of units (" Units ") at a price of $0.10 per Unit for gross proceeds of up to $2,000,000 (the " Offering "). Each Unit will consist of one common share of the Company (a " Common Share ") and one non-transferable common share... Read More

Toronto, Ontario--(Newsfile Corp. - November 19, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that its application to the IPON program (Intellectual Property Ontario) was approved. The IPON program... Read More

Toronto, Ontario--(Newsfile Corp. - October 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it has amended its agreement with Mayo Clinic, Rochester, Minnesota, US. The amendment is an... Read More

Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it has presented the most recent performance results of its TeloViewSMM prognostic test for... Read More

Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple... Read More

Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the US Centres of Medicare & Medicaid Services (CMS) which regulates the medical laboratories in the... Read More

Toronto, Ontario--(Newsfile Corp. - June 18, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the College of American Pathologists (CAP) has recently accepted Telo Genomics' submission to add Telo's... Read More

Toronto, Ontario--(Newsfile Corp. - June 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A) ("Telo" or the "Company"), is pleased to announce that results of the development, validation and implementation of its machine learning and Artificial Intelligence (AI) modules, used in its TeloView myeloma diagnostic tests, were presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting... Read More

Toronto, Ontario--(Newsfile Corp. - May 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), ( the "Company" or "Telo"), a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications in oncology, is thrilled to announce that the manuscript titled, "Three-dimensional telomere profiling predicts risk of progression in smoldering multiple... Read More

Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications in oncology is pleased to announce that the Company has signed a collaboration agreement with Emery Pharma ("Emery"). Emery is a full-service contract research organization... Read More

Toronto, Ontario--(Newsfile Corp. - April 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to... Read More

Toronto, Ontario--(Newsfile Corp. - April 2, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that patient recruitment for its minimal residual disease ("MRD") clinical trial has been initiated, with... Read More

Toronto, Ontario--(Newsfile Corp. - February 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") is pleased to announce that it has received the first patient sample for its clinical trial monitoring multiple myeloma ("MM") disease progression in post-treated patients. The study is being conducted in collaboration with McGill University and the Jewish General Hospital in Montreal, Canada.... Read More

Toronto, Ontario--(Newsfile Corp. - January 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo" ) is pleased to announce that it has engaged Trusted Health Advisors (THA), a market leader specialized in guiding commercialization programs of innovative diagnostics products in the USA. THA will work with Telo's team to refine and accelerate Telo's go-to-market and partnership deployment plan,... Read More

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "TELO") is pleased to announce that it has recently engaged Richard A. Bender MD, FACP, a veteran multiple myeloma ("MM") clinician, key opinion leader and medical diagnostics expert to establish and chair TELO's MM clinical advisory board (the "Advisory Board"). Driven by the progress of TELO's clinical studies announced on September 14, 2022, and as part of... Read More

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "TELO") is pleased to announce that the initial clinical validation stage of its ongoing clinical study for smoldering multiple myeloma ("SMM"), in collaboration with the Mayo Clinic, has completed review and analysis of its first cohort, consisting of 187 patients and has exceeded its targeted endpoints. In July 2022, the Company announced that it had... Read More

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "TELO") announces the completion of the laboratory processing and analysis of patient samples related to its multiple myeloma drug resistance clinical study. The patient samples were provided by the Mayo Clinic as part of an ongoing collaboration to evaluate the Company's prognostic technology for multiple myeloma ("MM"). TELO's study results have now been... Read More

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "TELO") is pleased to announce that it has commenced the processing of clinical samples to evaluate its TeloView platform to identify multiple myeloma ("MM") patients that are at high-risk of developing treatment resistance. This study is the second study being carried out in collaboration with the Mayo Clinic to evaluate the Company's prognostic technology... Read More